Initiation of TACTI-004 phase 3 trial in 1st line NSCLC
Filed with ASX · · 2 pages · English
Summary by 6ix AI
This pivotal trial will evaluate the combination of eftilagimod alfa with KEYTRUDA and chemotherapy against KEYTRUDA with chemotherapy and placebo. The receipt of regulatory approval from the Australian Therapeutic Goods Administration marks a significant milestone for the company.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Immutep
- Excellent Survival Data from INSIGHT-003 Trial in NSCLC
- Positive Data from Phase II Trial in Soft Tissue Sarcoma
- Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed
- Immutep receives A$3.6 million French R&D Tax Incentive
- New Positive Efficacy Data for Efti in Head and Neck Cancer
Later from Immutep
- Immutep Reports Promising New Data in Head and Neck Cancer
- Immutep announces initial safety data from IMP761 phase 1
- Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
- First patient dosed in phase 3 TACTI-004 lung cancer trial
- First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep